PINAL fusion has become a popular surgical technique. Instrumentation systems designed to provide segmental fixation and maintain stability and deformity correction have become increasingly refined and available. As more spinal fusions have been performed, problems such as fusion failure, pseudarthrosis, and infections at the bone-graft donor site have become more common.
an adjunct to an autogenous iliac crest bone graft in the canine spinal fusion model. These authors evaluated their results by performing CT scanning of the lumbar fusion, volumetric measurements of the total fusion mass, and manual mechanical stress experiments. The addition of rhBMP-2 significantly increased the volume of the bone grafts, as noted on CT scans. Recombinant human BMP-2, when added to an autograft, significantly increased the volume and maturity of the resulting fusion mass. Lovell and colleagues 11 investigated the action of rhBMP-2 on the growth of new bone in experimental spinal fusions. Spinal columns were examined using radiological and histological morphometric methods, which revealed a tendency for rhBMP-2-treated animals to have two to three times more new bone formation and a fivefold increase in the fusion rate than control animals. Treatment with rhBMP-2 increased the number and volumes of areas of de novo cartilage and woven bone formation. 11 The use of hMSCs and BMP genes in ex vivo gene therapy provides a local supply of precursor cells and a supraphysiological dose of osteoinductive molecules, which may promote bone formation in patients with inadequate hMSC populations due to age, osteoporosis, metastatic bone disease, iatrogenic depletion, or other metabolic derangements. Riew, et al., 16 demonstrated that BMP-2 could enhance the differentiation of MSCs by using an adenoviral vector that carried the hBMP-2 gene to transduce bone marrow-derived MSCs. Transduced autologous cells were reimplanted into the intertransverse process area. These authors concluded that it is possible to transduce MSCs successfully with the BMP-2 gene so that these cells will produce the BMP-2 protein in vitro and in vivo. Furthermore, the transduction process transforms these cells into an osteoprogenitor line capable of producing bone in vivo. These data indicate the feasibility of performing gene therapy with recombinant adenoviral vectors as a tool for enhancing spinal fusion. 16 In previous studies 7, 13, 17 we showed that cell-mediated gene therapy may be an effective treatment for augmenting new bone formation and, potentially, spinal fusion for two reasons. 1) In our cell-mediated gene therapy, the therapeutic protein is delivered by cells carrying the gene (transgene) for the therapeutic protein (rhBMP-2). Once the cells have engrafted in the host tissue, the expression of the transgene creates a steady supply of therapeutic protein in the vicinity of the fusion site. 2) In addition to stable expression of the gene, our model requires that cells carrying the gene in question will integrate, differentiate, and regenerate into bone cells via both autocrine and paracrine pathways. 7, 15, 17 Indeed, Dumont, 3 Wang, 19 and Helm 8 and their colleagues studied the efficacy of cell-mediated ex vivo gene therapy by using hMSCs transfected with BMP genes to promote spinal fusion in a rat model. Computerized tomography and histological analyses clearly demonstrated large volumes of bone at injection sites, resulting in successful spinal fusion and no evidence of nerve-root compression or local or systemic toxicity. The results of these studies indicate that hMSC-BMP ex vivo gene therapy may be useful in the induction of spinal fusion as well as in other related procedures, and that it certainly warrants further clinical development.
In the present study we sought to determine the duration of gene expression required for spinal fusion by using genetically engineered MSCs and to demonstrate the feasibility of regulating gene expression in this model. We hope this study will lead to the creation of a cell-mediated gene therapy for spinal fusion. To date there is no effective therapy for achieving spinal fusion without using either autologous or allogenic bone grafts. As shown earlier, these surgical techniques carry significant risks of morbidity as well as a high incidence of failed bone formation.
Materials and Methods

Generation of Genetically Engineered Clones
The genetic engineering of MSCs to express inducible rhBMP-2 has been described elsewhere. 13 The inducible human BMP-2 expression vector, ptTATop-BMP2, has a bidirectional promoter (TATA sequence) and consists of six tetracycline operators flanked by two transcriptional units with opposite orientations. Clockwise, the minimal adenovirus major late promoter, which spans positions nt 6001 to nt 6079, is followed by an EcoRI fragment from the hBMP-2 complementary DNA, an internal ribosomal entry site, a murine DHFR coding region, and a polyadenylation signal from the SV40 early region. Counterclockwise, the same minimal adenovirus major late promoter that spans positions nt 6001 to nt 6079 is followed by a ␤-globin intron, a complementary DNA encoding the fusion protein tTA, a transactivator regulated by tetracycline, and the ␤-actin polyadenylation site. In this vector, the level of the transactivator, which activates the bidirectional promoter, as well as the expression of hBMP-2 can be regulated by doxycycline, a derivative of tetracycline, yielding higher levels of gene expression as well as a greater frequency of inducible clones.
Cells from the C3H10T1/2 MSC line were transfected with a ptTATop-BMP2 plasmid vector that encodes for both the tetracycline transactivator and rhBMP-2. Control over the expression of rhBMP-2 in mice was achieved either by adding 0.5 mg/ml of doxycycline to the animals' drinking water or by withholding doxycycline from these animals.
Murine Model of Spinal Fusion
Thirty female immunocompetent C3H/HeN mice between the ages of 6 and 7 weeks were used in the experiment. Each animal received an injection of 2 ϫ 10 6 genetically engineered MSCs into a paravertebral muscle in the lumbar region. In addition, three female FVB/N transgenic mice harboring the luciferase gene under the control of the human osteocalcin promoter were used. 9 All animals were provided free access to food and water throughout the entire study. The study protocol was evaluated and approved by the animal ethics committee of Hebrew University in Jerusalem.
Animal Preparation. Anesthesia was induced in each mouse by an intraperitoneal injection of ketamine-xylazine solution (1 l/g body weight). Fur covering the back of the animal was shaved using an electric hair shaver, and the skin was prepared by rubbing it with a swab that had been dipped in isopropanol. Mesenchymal stem cells (2 ϫ 10 6 ) suspended in 100 l phosphate-buffered saline were injected into a posterior paravertebral muscle of the lumbar spine, which was found at the L2-6 level by manual palpation. Ten mice serving as a negative control group received doxycycline (0.5 mg/ml supplementation in the animals' drinking water) and 20 mice constituting the experimental group received doxycycline for different time periods during the 8-week study. The FVB/N mice, which were used for bioluminescence imaging, did not receive doxycycline at any time during the experiment.
To determine the minimal duration of BMP-2 expression required to induce bone formation, mice in the experimental group were maintained without access to doxycycline for 3, 7, or 30 days, and mice in the control group were maintained while given doxycycline for 30 days.
All animals participating in this study endured the procedure well. There were no instances of infection or neurological injury and no sign of toxicity or hypersensitivity in response to the injected engineered MSCs.
Evaluation of Bone Formation In Vivo
At 4 and 8 weeks postinjection, bone formation in the paraspinal region of the injected animals was evaluated by performing a histological study in which H & E staining was used. A quantitative morphometric analysis of the fusion mass was undertaken by longitudinally following bone formation with the aid of a micro-CT scanner (CT 40; Scanco Medical AG, Bassersdorf, Switzerland). For each time point the area of new bone formation in the injection site was scanned, marked, and measured using micro-CT three-dimensional reconstruction and analysis of total bone volume. Bone volume was measured and is reported in cubic millimeters.
Imaging of Osteogenic Induction In Vivo
In vivo imaging of the osteogenic induction exerted by the engineered MSCs was performed using Oc-Luc transgenic mice and a light-detection cooled CCD. The cooled CCD camera tracked osteocalcin expression by examining luciferase activity, which was detected after each mouse was given an intraperitoneal injection of beetle luciferin (Promega Corp., Madison, WI) in phosphate-buffered saline at a dose of 126 mg/kg body weight. The luciferin was injected 10 minutes before light emission was monitored. Bioluminescence was measured by examining the animals with the cooled CCD camera at 2 and 4 weeks postinjection. Total integrated light units measured by the cooled CCD at the injection site during a 120-second period was presented as a ratio over the total integrated light units measured in the tail of the same mouse during the same time period. Quantitative analysis of luciferase expression was performed using Meta Imaging series Version 4.6 software (Universal Imaging Corp., Downingtown, PA), relying on a constant measurement field for all time points. Results are presented in relative luciferase units.
Results
Genetically Engineered MSCs Form New Bone and Achieve Spinal Fusion
Genetically engineered MSCs were generated to harbor the ptTATop-BMP2 construct encoding for two genes: the tetracycline-sensitive transactivator and the hBMP-2 gene, both of which were under the control of a tetracycline-sensitive promoter. 13 Under normal conditions the tetracycline-sensitive transactivator binds to the tetracycline-sensitive promoter and initiates hBMP-2 gene expression. In the presence of tetracycline or its analog doxycycline, however, the antibiotic agent binds to the transactivator and prevents its binding to the promoter, thus preventing the expression of hBMP-2 and that of the transactivator as well.
Animals injected with genetically engineered MSCs and maintained with or without doxycycline for 8 weeks underwent micro-CT scanning at 4 and 8 weeks postinjection. Three-dimensional CT reconstructions were created to determine the extent of bone development and fusion.
As early as the 4th week postinjection, there was extensive bone formation in areas adjacent and adherent to the posterior elements of the spine in all animals in the experimental group (Fig. 1) . No new bone formation was detected in any of the doxycyline-treated (control) animals that were examined.
A longitudinal micro-CT study of newly formed bone revealed a larger amount of bone as well as greater maturation of the fusion mass in the 8th week postinjection (Fig. 1E ) compared with the 4th week. When the newly formed bone was viewed as a fusion mass, we were able to show that it covered two or three spine segments. The extensive bone formation on and adjacent to the posterior elements of the spine actually constituted a bridging mass of bone fusion above and covering several spinal segments. A quantitative analysis of this fusion mass determined that the bone volume was in the range of 23 to 28 mm 3 (Fig. 1B) . Standard staining with H & E revealed a well-organized fusion mass on the posterior aspect of the mouse spines. Light microscopy of the bone architecture revealed an organized fusion mass with a lamellar microstructure, rather than an unorganized woven mass of weak bone (Fig. 2) .
In Vivo Bioluminescence Imaging of Osteogenesis
With the aid of the cooled CCD camera we obtained in vivo images of osteogenesis induced by the implanted engineered MSCs. Measurements of luciferase gene expression at the site of implantation 2 and 4 weeks postinjection indicated higher levels of osteocalcin expression as time passed (Fig. 3) . These results clearly demonstrated the paracrine effect of the implanted engineered MSCs, which leads to an active osteogenic process for at least 4 weeks.
Duration of rhBMP-2 Induction
Genetically engineered MSCs were injected into the paraspinal muscles of mice and the animals were treated with doxycycline for different time periods. The animals were given doxycycline for 30 days or deprived of doxycycline treatment for 3, 7, or 30 days following cell implantation, after which doxycycline was added to the drinking water until Day 30, the last day of the experiment. The animals included in this study were anesthetized and examined noninvasively by performing in vivo micro-CT scanning. For purposes of comparison we focused on measuring bone volume only in the same spinal region-L2-4-in all animals. Given the limited area of our focus, the amount of bone that was measured was smaller than the overall newly formed bone, as depicted in Fig. 1 . The results indicated that a 3-day deprivation of doxycycline treatment was not sufficient to obtain new bone formation. A 7-day deprivation of doxycycline, however, was sufficient to allow for new bone formation and spinal fusion (Fig. 4) . Moreover, our data indicated that the longer the duration of rhBMP-2 expression the greater the amount of bone volume that formed (Fig. 4) .
Discussion
Recent publications have shown the feasibility and logic of using MSCs as precursors of bone-graft formation. Untreated or genetically manipulated MSCs have been separated, characterized, and used to augment the formation of new bone tissue in vivo. [6] [7] [8] 15, 17, 18 Moreover, regulation of gene expression has been shown to be a means to control and monitor bone formation in vivo. 5, 6, 13 In the present study we wished to carry these procedures one step farther by joining MSC-mediated gene therapy with regulation of gene expression to obtain spinal fusion. Genetically engineered MSCs that conditionally expressed the rhBMP-2 gene under the control of tetracycline were used in the experiment.
Following the injection of genetically engineered MSCs into the paraspinal muscles, histological and structural analyses of the results revealed extensive bone formation as soon as the 4th week postinjection in areas adjacent to or touching the posterior elements of the spine in all animals in the experimental group. On the other hand, there was no bone formation in any animal in the control group. A longitudinal micro-CT study of new bone formation revealed more bone content and greater maturation of the fusion mass 8 weeks postinjection than those measured 4 weeks earlier. Bone quality tests demonstrated that the bone was truly lamellar, rather then dystrophic woven bone. When we viewed the new bone formation as a fusion mass, we were able to show that this mass covered two to three spinal segments. The extensive bone formation identified on and adjacent to the posterior elements of the spine was actually a bridging fusion mass extending above and across several spinal segments (Fig. 1) . Moreover, our results indicate a spatial and temporal link between bone formation and rhBMP-2 expression, as indicated by our experiments with limited duration of BMP-2 expression. As in our previous study, 14 here too we found that following cell implantation, a minimum of 7 days of BMP-2 expression is required to obtain bone formation.
The cooled CCD imaging system used to detect the paracrine osteogenic effect of the engrafted MSCs revealed the expression of osteocalcin, measured by the luciferase bioluminescence signal at the site of transplantation (Fig.  3 ). An examination of the animals at 2 and 4 weeks postinjection demonstrated increasing luminescence, which represented an increasingly active osteogenic process.
The current results confirm and advance some of our earlier findings on the formation and repair of bone tissue 6, 7, 15, 17 and on spinal fusion. 3, 8, 19 These studies on the efficacy of cell-mediated ex vivo gene therapy, in which human-and animal-derived MSCs transfected with BMP genes are used to promote spinal fusion, clearly demonstrated large volumes of new bone at the injection sites, resulting in successful spinal fusion and no evidence of nerve-root compression or local or systemic toxicity. It is also important to note that no indications of tumor formation or cell transformation was observed at the site of cell implantation. The results of these studies lead us to postu- late that hMSC-BMP ex vivo gene therapy may be useful in inducing spinal fusion as well as in other related procedures, and that it certainly warrants further clinical development.
Conclusions
The present study builds on knowledge gained by previous MSC-related gene therapies by introducing tetracycline regulation of gene expression. We have shown that a 7-day expression of rhBMP-2 is sufficient to obtain spinal fusion. Moreover, we have shown that as the duration of rhBMP-2 expression is increased, the amount of newly formed bone tissue is increased as well (Fig. 4) . Thus, it is possible to monitor the extent of spinal fusion by monitoring the duration of gene expression.
Based on this technology, it is our hope that in the future MSCs injected into a site of bone injury will grow and differentiate to form an autogenous bone graft, which regulated by an inducible genetic element will promote bone fusion. This may reduce the need for iliac crest bone grafts, which are currently in use and are associated with a significant risk of morbidity. Future studies will enable us to use these MSCs to form bone of superior quality and reduce the incidence of nonunion or pseudarthrosis, which plagues neurosurgery and orthopedic surgery. 1, 12 It is our hope that eventually the outcomes of these studies will improve techniques of spinal surgery as well as of other subspecialities of neurosurgery and orthopedic surgery.
